Literature DB >> 31276364

Ambidextrous Approach To Disrupt Redox Balance in Tumor Cells with Increased ROS Production and Decreased GSH Synthesis for Cancer Therapy.

Longfa Kou1,2, Rui Sun1, Shuyi Xiao1, Yawen Zheng3, Zhiwei Chen1, Aimin Cai1, Hailun Zheng1, Qing Yao3, Vadivel Ganapathy2, Ruijie Chen1.   

Abstract

An effective steady-state redox balance is maintained in cancer cells, allowing for protection against oxidative stress and thereby enhancing cell proliferation and tumor growth. Disruption of this redox balance would increase the cellular content of reactive oxygen species (ROS) and potentiate oxidative stress-induced cell death in tumor cells, thus representing an effective strategy for cancer treatment. Glutathione (GSH) is a major reducing agent, and its cellular levels are determined at least partly by the availability of cysteine via xCT (SLC7A11)-mediated entry of cystine into cells. We developed a nanoplatform using ZnO nanoparticles (NPs) as a carrier, loaded with salicylazosulfapyridine (SASP), and stabilized with DSPE-PEG, to form ultra-small NPs (SASP/ZnO NPs). The goal of this NP strategy is to disrupt the redox balance in cells by two mechanisms: increased generation of ROS and decreased synthesis of GSH. Such an approach would be effective in killing tumor cells. As expected, the SASP/ZnO NPs enhanced ROS production because of ZnO and impaired GSH synthesis because of SASP-induced inhibition of xCT (SLC7A11) transport function. As a consequence, treatment of tumor cells with SASP/ZnO NPs in vitro and in vivo resulted in a synergistic disruptive effect on redox balance in tumor cells and induced cell death and decreased tumor growth. This ambidextrous approach has potential in cancer therapy by combining two complementary pathways to disrupt the redox balance in tumor cells.

Entities:  

Keywords:  ROS generation; ZnO nanoparticles; cancer therapy; glutathione synthesis; redox balance; salicylazosulfapyridine (SASP); xCT inhibition

Year:  2019        PMID: 31276364     DOI: 10.1021/acsami.9b09784

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  12 in total

1.  Alantolactone-loaded chitosan/hyaluronic acid nanoparticles suppress psoriasis by deactivating STAT3 pathway and restricting immune cell recruitment.

Authors:  Ruijie Chen; Yuan-Yuan Zhai; Lining Sun; Zeqing Wang; Xing Xia; Qing Yao; Longfa Kou
Journal:  Asian J Pharm Sci       Date:  2022-02-27       Impact factor: 9.273

2.  Bilirubin Protects Transplanted Islets by Targeting Ferroptosis.

Authors:  Qing Yao; Rui Sun; Shihui Bao; Ruijie Chen; Longfa Kou
Journal:  Front Pharmacol       Date:  2020-06-16       Impact factor: 5.810

3.  Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment.

Authors:  Shihui Bao; Hailun Zheng; Jinyao Ye; Huirong Huang; Bin Zhou; Qing Yao; Guangyong Lin; Hailin Zhang; Longfa Kou; Ruijie Chen
Journal:  Front Pharmacol       Date:  2021-03-19       Impact factor: 5.810

4.  Bioadhesive hydrogel comprising bilirubin/β-cyclodextrin inclusion complexes promote diabetic wound healing.

Authors:  Qing Yao; Yannan Shi; Xing Xia; Yingying Tang; Xue Jiang; Ya-Wen Zheng; Hailin Zhang; Ruijie Chen; Longfa Kou
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

Review 5.  The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role.

Authors:  Jing Zuo; Zhe Zhang; Maomao Li; Yun Yang; Bohao Zheng; Ping Wang; Canhua Huang; Shengtao Zhou
Journal:  Mol Cancer       Date:  2022-01-26       Impact factor: 27.401

Review 6.  Redox dyshomeostasis strategy for tumor therapy based on nanomaterials chemistry.

Authors:  Yelin Wu; Yanli Li; Guanglei Lv; Wenbo Bu
Journal:  Chem Sci       Date:  2022-01-12       Impact factor: 9.825

Review 7.  The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer.

Authors:  Nidhi Jyotsana; Kenny T Ta; Kathleen E DelGiorno
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

Review 8.  ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer.

Authors:  Gan Huang; Shu-Ting Pan
Journal:  Oxid Med Cell Longev       Date:  2020-07-22       Impact factor: 6.543

9.  Drug discovery and formulation development for acute pancreatitis.

Authors:  Xue Jiang; Ya-Wen Zheng; Shihui Bao; Hailin Zhang; Ruijie Chen; Qing Yao; Longfa Kou
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

10.  Bioinspired biliverdin/silk fibroin hydrogel for antiglioma photothermal therapy and wound healing.

Authors:  Qing Yao; Qing-Hua Lan; Xinyu Jiang; Chu-Chu Du; Yuan-Yuan Zhai; Xiaohan Shen; He-Lin Xu; Jian Xiao; Longfa Kou; Ying-Zheng Zhao
Journal:  Theranostics       Date:  2020-09-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.